↓ Skip to main content

Treatment of Generalized Dystonia

Overview of attention for article published in Current Treatment Options in Neurology, April 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

wikipedia
2 Wikipedia pages

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
108 Mendeley
Title
Treatment of Generalized Dystonia
Published in
Current Treatment Options in Neurology, April 2011
DOI 10.1007/s11940-011-0122-0
Pubmed ID
Authors

Naomi Lubarr, Susan Bressman

Abstract

The armamentarium for clinicians treating patients with generalized dystonia, previously restricted to only a few oral medications that often caused intolerable side effects, has been radically expanded in the past decade with the widespread application of deep brain stimulation (DBS). With DBS, patients who in the past would have been restricted to a life of severe motor disability from a young age can now lead lives with only minimal symptoms. Although DBS should therefore be considered as a treatment option for any patient with severe, medically refractory dystonia, important questions remain about patient selection, including what factors predict which patients will benefit from DBS, and when in the course of disease DBS should be performed. Reports show that patients with primary dystonia respond better than those with secondary dystonia, and limb and axial muscles may improve more than cranial dystonia. Some studies also suggest that shorter duration of disease may be associated with better outcomes. However, it is important to note that even among those thought to respond best to DBS, i.e. patients with primary generalized dystonia, there is a subset that will have significant and sustained clinical benefit with oral medications. It is therefore important that adequate trials of oral medications be attempted prior to referral for surgery. On the other hand, once it is clear that medical therapies are not providing significant benefit or are not well tolerated, children with disabling generalized primary dystonia should be referred quickly for DBS. The dramatic clinical improvement that can be seen with DBS can restore normal or near-normal functioning and avoid the physical and emotional costs of an extended period of decreased physical and social functioning. In general, a levodopa trial should always be considered as the first treatment at the time of presentation of any patient with childhood-onset limb dystonia, in order to exclude dopa-responsive dystonia. Once a diagnosis of primary generalized dystonia is established, we typically initiate treatment with trihexyphenidyl, titrating slowly up to a high dose. We then frequently add baclofen as a second agent. If clinical improvement at that point is inadequate and the dystonia is causing significant functional impairment, we then consider referral for DBS.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 <1%
Germany 1 <1%
Canada 1 <1%
Brazil 1 <1%
Unknown 104 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 19%
Student > Master 16 15%
Other 14 13%
Student > Bachelor 12 11%
Student > Ph. D. Student 10 9%
Other 18 17%
Unknown 18 17%
Readers by discipline Count As %
Medicine and Dentistry 34 31%
Neuroscience 11 10%
Psychology 10 9%
Nursing and Health Professions 8 7%
Engineering 4 4%
Other 14 13%
Unknown 27 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2013.
All research outputs
#7,452,489
of 22,783,848 outputs
Outputs from Current Treatment Options in Neurology
#174
of 471 outputs
Outputs of similar age
#39,998
of 109,332 outputs
Outputs of similar age from Current Treatment Options in Neurology
#2
of 6 outputs
Altmetric has tracked 22,783,848 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 471 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,332 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.